Bristol-Myers Squibb Co logo

Bristol-Myers Squibb Co (BMY)

Market Open
29 Apr, 19:31
NYSE NYSE
$
49. 40
+0.94
+1.93%
$
124.26B Market Cap
- P/E Ratio
2.4% Div Yield
919,882 Volume
- Eps
$ 48.46
Previous Close
Day Range
48.11 49.47
Year Range
39.35 63.33

Summary

BMY trading today higher at $49.4, an increase of 1.93% from yesterday's close, completing a monthly decrease of -18.72% or $11.37. Over the past 12 months, BMY stock lost -13.24%.
BMY pays dividends to its shareholders, with the most recent payment made on Feb 03, 2025. The next announced payment will be in In 2 days on May 01, 2025 for a total of $0.62.
The last earnings report, released on Apr 25, 2025, missed the consensus estimates by -1.53%. On average, the company has fell short of earnings expectations by -0.34%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 14 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track BMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

BMY Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 5 hours ago
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?

BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.

Zacks | 1 day ago
5 Positives From Bristol-Myers Squibb's Q1 2025 Results

5 Positives From Bristol-Myers Squibb's Q1 2025 Results

Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised positively, beating estimates by 20%. BMS upgraded its 2025 guidance a bit too, reducing expected revenue shrinkage to 4.1% and raising non-GAAP EPS expectations by 2.24%.

Seekingalpha | 4 days ago

Bristol-Myers Squibb Co (BMY) FAQ

What is the stock price today?

The current price is $49.40.

On which exchange is it traded?

Bristol-Myers Squibb Co is listed on NYSE.

What is its stock symbol?

The ticker symbol is BMY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 124.26B.

Has Bristol-Myers Squibb Co ever had a stock split?

No, there has never been a stock split.

Bristol-Myers Squibb Co Profile

Drug Manufacturers - General Industry
Healthcare Sector
Dr. Christopher S. Boerner Ph.D. CEO
NYSE Exchange
US1101221083 ISIN
Germany Country
- Employees
4 Apr 2025 Last Dividend
7 Aug 2001 Last Split
- IPO Date

Overview

Bristol-Myers Squibb Company is an eminent global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative biopharmaceutical products. With a spectrum of treatments covering hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company has established a significant footprint in the healthcare sector. Initially founded as Bristol-Myers Company in 1887, it has evolved over the decades to become a leader in the biopharmaceutical industry, headquartered in Princeton, New Jersey. The company's operational reach spans globally, selling products through a diversified channel mix including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Products and Services

  • Eliquis: Used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • Opdivo: A versatile anti-cancer medication approved for a wide range of cancers including bladder, blood, colorectal, head and neck, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), lung, melanoma, mesothelioma, stomach, and esophageal cancer.
  • Pomalyst/Imnovid: Designed for the treatment of multiple myeloma, providing vital options for patients with this challenging form of cancer.
  • Orencia: Offers relief for individuals suffering from active rheumatoid arthritis and psoriatic arthritis, aiming to improve quality of life and reduce symptoms.
  • Sprycel: Specifically targeted at treating Philadelphia chromosome-positive chronic myeloid leukemia, a particular type of leukemia characterized by the presence of an abnormal chromosome.
  • Yervoy: This medication is used for the treatment of patients with unresectable or metastatic melanoma, offering a beam of hope for those battling this form of skin cancer.
  • Empliciti: Another option in the fight against multiple myeloma, providing an additional avenue for treatment for patients.
  • Abecma: Crafted for the treatment of relapsed or refractory multiple myeloma, Abecma offers a new horizon for patients who have not responded to previous treatments.
  • Reblozyl: A therapeutic option for the treatment of anemia, focusing on a condition that can severely impact the overall health and well-being of patients.
  • Opdualag: Specifically indicated for the treatment of unresectable or metastatic melanoma, enhancing the arsenal against this aggressive skin cancer.
  • Zeposia: Approved to treat relapsing forms of multiple sclerosis, this medication aims to reduce the frequency of relapses and slow the disease's progression.
  • Breyanzi: Used for the treatment of relapsed or refractory large B-cell lymphoma, Breyanzi provides a valuable tool in the fight against this type of cancer.
  • Onureg: A treatment option for acute myelogenous leukemia (AML), offering new hope for patients with this aggressive form of leukemia.
  • Inrebic: Targets myelofibrosis, a serious bone marrow disorder, by offering patients a chance for improved outcomes and symptom relief.
  • Camzyos: Focuses on the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), aimed at enhancing functional capacity and reducing symptoms in affected patients.
  • Sotyktu: Provides relief for patients suffering from moderate-to-severe plaque psoriasis, offering a new approach in managing this chronic skin condition.
  • Augtyro: Specifically developed for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), marking a significant step forward in targeted cancer therapy.
  • Revlimid: An oral immunomodulatory drug critical for the treatment of multiple myeloma, playing a key role in managing this form of cancer.
  • Abraxane: Used to treat breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer, Abraxane extends therapeutic options for patients facing these serious diseases.

Contact Information

Address: Route 206 & Province Line Road
Phone: 609 252 4621